iHIVARNA-01 is a novel therapeutic vaccine for the treatment of HIV-1-infected patients based
on in vivo modification of DCs. It consists of HIVACAT-TriMix: mRNA encoding a mixture of APC
activation molecules (CD40L, a constitutively active variant of TLR4 and CD70) and the HIV
target antigens contained in HIVACAT to be administered through the intranodal route.
iHIVARNA-01 aims to achieve the 'functional cure' of HIV infection, i.e. controlling viral
replication in the absence of anti-retroviral therapy.